Citi lowered the firm’s price target on Innate Pharma to $8 from $12 and keeps a Buy rating on the shares. The analyst updated biotechnology models post the Q2 reports.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
